Table 1.
Clinical sampling framework for including men in the study.
| Group | Clinical outcome | PSA test | Urological symptoms (n) | Total (n) | Study identifier |
|---|---|---|---|---|---|
| 1 | Declined PSA | Declined | 1 | 1 | 1 |
| 2 | Normal PSA result | Undertaken test | 8 | 11 | 2–12 |
| 3 | PSA raised; no biopsy | Undertaken test | 2 | 3 | 13–15 |
| 4 | PSA raised; prostate cancer not diagnosed on biopsy | Undertaken test | 4 | 5 | 16–20 |
| 5 | PSA raised; prostate cancer diagnosed on biopsy | Undertaken test | 2 | 4 | 21–24 |
| 6a | — | Uncertain of undertaking test | 1 | 1 | 25 |
| 6b | — | Uncertain of the result | 2 | 3 | 26–28 |
| Total | 20 | 28 | |||
PSA = prostrate specific antigen.